AUPS337802A0 - Method of screening for antidiabetic agents - Google Patents
Method of screening for antidiabetic agentsInfo
- Publication number
- AUPS337802A0 AUPS337802A0 AUPS3378A AUPS337802A AUPS337802A0 AU PS337802 A0 AUPS337802 A0 AU PS337802A0 AU PS3378 A AUPS3378 A AU PS3378A AU PS337802 A AUPS337802 A AU PS337802A AU PS337802 A0 AUPS337802 A0 AU PS337802A0
- Authority
- AU
- Australia
- Prior art keywords
- screening
- antidiabetic agents
- antidiabetic
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPS3378A AUPS337802A0 (en) | 2002-07-04 | 2002-07-04 | Method of screening for antidiabetic agents |
AU2003245051A AU2003245051A1 (en) | 2002-07-04 | 2003-07-04 | Method of screening for antidiabetic agents |
PCT/JP2003/008523 WO2004005550A2 (en) | 2002-07-04 | 2003-07-04 | Method of screening for antidiabetic agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPS3378A AUPS337802A0 (en) | 2002-07-04 | 2002-07-04 | Method of screening for antidiabetic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AUPS337802A0 true AUPS337802A0 (en) | 2002-07-25 |
Family
ID=3836934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AUPS3378A Abandoned AUPS337802A0 (en) | 2002-07-04 | 2002-07-04 | Method of screening for antidiabetic agents |
Country Status (2)
Country | Link |
---|---|
AU (1) | AUPS337802A0 (en) |
WO (1) | WO2004005550A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2863275B1 (en) * | 2003-12-09 | 2007-08-10 | Biomerieux Sa | METHOD FOR THE DIAGNOSIS / PROGNOSIS OF BREAST CANCER |
GB2436837A (en) * | 2006-04-05 | 2007-10-10 | Univ Open | Culturing adipocytes |
US20090318465A1 (en) * | 2006-09-21 | 2009-12-24 | Rosalind Adaikalasamy Marita | Method for identifying compounds that act as insulin-sensitizers |
WO2008134727A1 (en) * | 2007-04-30 | 2008-11-06 | The Board Of Regents Of The University Of Texas System | Methods and compositions for treatment of reperfusion injury and other cardiac conditions |
CN105445472A (en) * | 2015-11-13 | 2016-03-30 | 泰山医学院 | Method and kit for detecting activity of micro-molecular G protein Rap1 |
CN107353205B (en) * | 2017-07-27 | 2020-02-07 | 中国科学院新疆理化技术研究所 | Ester compound in nigella glandulifera Freyn seeds as well as preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2386750A1 (en) * | 1999-10-22 | 2001-05-03 | Merck & Co. Inc. | Pharmaceuticals for treating obesity |
-
2002
- 2002-07-04 AU AUPS3378A patent/AUPS337802A0/en not_active Abandoned
-
2003
- 2003-07-04 WO PCT/JP2003/008523 patent/WO2004005550A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2004005550A3 (en) | 2004-04-15 |
WO2004005550A2 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003277596A1 (en) | Method of deuterization | |
AU2003269126A1 (en) | Method of combining materials | |
AU2003277663A1 (en) | Screening method | |
AU2002249467A1 (en) | Screening method | |
AUPS096002A0 (en) | Method of construction | |
AU2003242340A1 (en) | Novel screening method | |
AUPS337802A0 (en) | Method of screening for antidiabetic agents | |
AU2002247215A1 (en) | Method for screening compounds | |
AU2003254579A1 (en) | Methods of screening for schizophrenia | |
AU2003227268A1 (en) | Novel screening method | |
AU2003253813A1 (en) | Method for colpoplasty | |
AU2003202622A1 (en) | A method of screening | |
AU2003285503A1 (en) | Screening method | |
AU2003245051A1 (en) | Method of screening for antidiabetic agents | |
AU2003251156A1 (en) | Screening for anti-ovulatory compounds | |
AU2003242342A1 (en) | Novel screening method | |
AU2002952966A0 (en) | Screening apparatus | |
AU2003217008A1 (en) | Screening method | |
AU2002354247A1 (en) | Screening method | |
AU2003248955A1 (en) | Screening method | |
AU2003235310A1 (en) | Novel screening method | |
AU2003210099A1 (en) | New method | |
AU2003244107A1 (en) | Methods of searching for substance having antidiabetic effect | |
AU2003241904A1 (en) | Novel method of screening | |
AU2003280725A1 (en) | Screening method |